Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) is celebrating some positive patient outcomes in the Phase 2 clinical trial for its asset RECCE® 327 Topical Gel (R327G), which targets Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
Robust therapeutic response
With 20 of the 30 enrolled patients now dosed, interim results reveal a robust therapeutic response – all patients have met the primary endpoints of either achieving a complete cure or significant improvement.
The trial, anticipated to conclude by the end of 2024, again underscores R327G’s efficacy and safety, with no serious adverse events (SAEs) reported.
These positive outcomes reinforce the potential of R327G to address challenging bacterial infections, including diabetic foot infections.
Chief medical advisor Dr Alan Dunton said: “These interim results reflect a remarkable advancement in our journey to address critical unmet medical needs in anti-infective therapies.
“The robust response we are seeing with R327G is encouraging, especially as we near completion of the Phase 2 trial.
“Achieving a response of complete cure or notable improvement in all patients treated so far highlights the potential impact of R327G in treating complex bacterial infections.”
The promising data supports R327G’s continued development as a pioneering synthetic anti-infective topical therapy, in alignment with the recent non-Data Safety Monitoring Board (DSMB) endorsement.
The ABSSSI market, which is expected to reach US$26 billion by 2032, presents a significant opportunity for R327G’s application upon regulatory approval.
About Recce Pharmaceuticals
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) is advancing a suite of synthetic anti-infectives to combat antibiotic-resistant superbugs and emerging viral pathogens.
The company’s flagship compounds, including RECCE® 327, have earned recognition from the World Health Organization (WHO) and the US Food and Drug Administration (FDA) under the GAIN Act.